10-K: Crescent Biopharma's 2025 10-K: Oncology Pipeline & Funding

Crescent Biopharma details its oncology pipeline, strategic partnerships, and financial position in its 2025 annual report, highlighting significant capital raises and ongoing clinical development.

Summary

• Crescent Biopharma, a clinical-stage biotechnology company, is focused on developing transformative therapies for cancer, with two distinct strategies: a PD-1 x VEGF bispecific antibody (CR-001) and a portfolio of antibody-drug conjugates (ADCs).
• The company initiated a global Phase 1/2 trial for CR-001 (the ASCEND trial) in February 2026, targeting up to eight solid tumor types.
• CR-002 is a PD-L1-directed ADC with a topoisomerase toxin, with a Phase 1/2 trial anticipated to begin in the second half of 2026.
• CR-003 (SKB105) is an integrin beta-6 (ITGB6)-directed ADC, licensed exclusively from Kelun outside Greater China, with a Phase 1/2 trial anticipated in China in Q1 2026.
• A key strategy involves combining CR-001 with ADC therapies, with the first CR-001 ADC combination trial anticipated in H2 2026.
• The company reported a net loss of $153.9 million for the twelve months ended December 31, 2025, and an accumulated deficit of $171.8 million.
• Cash and cash equivalents stood at $213.2 million as of December 31, 2025, following significant capital raises.
• The company expects existing cash to fund operations for at least twelve months from the filing date.
• The ADC Paragon Option Agreement for Former CR-003 will terminate around March 26, 2026, as the company will no longer license intellectual property rights for it, shifting focus to CR-003 (SKB105) from Kelun.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company faces significant financial losses typical of its early stage, the substantial capital raises and strategic partnerships provide a strong foundation for advancing a promising oncology pipeline, particularly with CR-001 and the ADC programs.

Positives

• Successfully raised approximately $142.3 million in net proceeds from the Pre-Closing Financing and $171.9 million in net proceeds from a Private Placement, significantly bolstering cash reserves to $213.2 million as of December 31, 2025.
• Initiated a global Phase 1/2 clinical trial (ASCEND trial) for CR-001 in February 2026, covering up to eight solid tumor types, demonstrating progress in its lead program.
• Secured an exclusive license for SKB105 (CR-003), an ITGB6-directed ADC, outside Greater China from Kelun, expanding the ADC pipeline with a promising asset.
• Established a strategic partnership with Kelun, granting them exclusive rights to CR-001 in Greater China, which is expected to accelerate global development and provide valuable clinical data.
• Preclinical data for CR-001 shows cooperative binding to PD-1 in the presence of VEGF, similar to ivonescimab, which has demonstrated superior progression-free survival over Keytruda.
• CR-002 demonstrated more potent cell toxicity in vitro and superior antitumor activity in a xenograft mouse model compared to benchmark ADCs.
• CR-003 (SKB105) showed superior cell internalization and potent in vivo antitumor activity in CDX tumor models compared to SGN-B6A, along with enhanced stability and superior half-life in mice.

Negatives

• Incurred a significant net loss of $153.9 million for the twelve months ended December 31, 2025, and has an accumulated deficit of $171.8 million since inception.
• Has not generated any revenue from product sales and does not anticipate doing so for the foreseeable future, relying heavily on equity and/or debt financings.
• Operates as a clinical-stage biotechnology company with a limited operating history and has not completed any clinical trials for its own products, indicating high inherent risk.
• Substantially dependent on the success of its lead program, CR-001, and other ADC programs (CR-002, CR-003), with no assurance of successful clinical trials or regulatory approval.
• Reliance on third-party manufacturers and CROs introduces risks related to production difficulties, supply chain issues, and compliance with regulatory requirements.
• The ADC Paragon Option Agreement for Former CR-003 is being terminated, indicating a shift away from a previously pursued preclinical asset.

Risks

• The company is a clinical-stage biotechnology company with a limited operating history, has not completed any clinical trials, and has no products approved for commercial sale, leading to historical and anticipated future losses.
• There is no guarantee of raising additional capital on acceptable terms, or at all, which could force delays, scaling back, or discontinuation of development programs, or lead to relinquishing rights to product candidates.
• Raising additional capital may cause dilution to shareholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Drug development and obtaining regulatory approval is costly, time-consuming, highly uncertain, and may not be successful, particularly for the lead program CR-001 and ADC programs CR-002 and CR-003.
• Failure to meet chemistry, manufacturing, and control requirements for programs could prevent product approval.
• Significant competition exists from major pharmaceutical and biotechnology companies with greater resources and more advanced pipelines.
• Failure to achieve projected development goals in announced timeframes could delay commercialization and increase expenses, negatively impacting share price.
• Use of product candidates could be associated with adverse side effects or safety risks, potentially delaying or precluding approval, or limiting commercial profile.
• The company may attempt to obtain accelerated approval, but if unsuccessful, it may require additional, costly, and time-consuming clinical trials.
• Limited resources may be expended on less profitable programs, causing missed opportunities for more successful ones.
• Approved products may not achieve adequate market acceptance among clinicians, patients, and payors, hindering revenue generation.
• Certain programs may compete with other internal programs, potentially limiting future revenue.
• Data from clinical trials conducted outside the United States may not be accepted by the FDA, requiring additional costly and time-consuming trials.
• Extensive ongoing regulatory obligations and review post-approval may result in significant additional expense and penalties for non-compliance.
• Current and future U.S. healthcare reform legislation or regulation (e.g., ACA, IRA, One Big Beautiful Bill Act) may increase the difficulty and cost of obtaining coverage and commercializing products, and adversely affect pricing.
• Exposure to U.S. federal, state, and foreign healthcare fraud and abuse laws, anti-corruption laws, and data privacy/security regulations could lead to significant fines, liabilities, and reputational harm.
• Reliance on third-party licensing arrangements (Paragon, Kelun) means business success depends on their efforts and compliance, and potential disputes or terminations could harm the business.
• Reliance on third parties for preclinical studies and clinical trials means limited direct control over their performance, potentially leading to delays or compromised data.
• Reliance on third parties operating in China (e.g., WuXi Biologics, Kelun) exposes the company to additional risks from U.S. legislation (e.g., BIOSECURE Act), trade restrictions, and geopolitical instability.
• Inability to use third-party manufacturing sites or difficulties in production could adversely affect the business.
• Dependence on key personnel and difficulties in managing organizational growth could harm business strategy implementation.
• Estimates of market opportunity and forecasts of market growth may be inaccurate, and actual growth may not meet expectations.
• Internal information technology systems or those of third-party providers may fail or suffer security/data privacy breaches, leading to costs, revenue loss, liabilities, and operational disruption.
• Adverse legislative or regulatory tax changes could negatively impact financial condition.
• Future acquisitions or strategic alliances may not realize expected benefits.
• Cash balances exceeding federally-insured limits at financial institutions pose a risk of loss in case of bank failures.
• Preferred directors elected by Series A Preferred Shareholders have significant influence over board matters, potentially conflicting with ordinary shareholders' interests.
• Cayman Islands law and Articles of Association contain anti-takeover provisions that could discourage changes in control.
• Exclusive forum provision in Articles of Association designates Cayman Islands courts for certain disputes, potentially limiting shareholders' ability to choose a favorable judicial forum.
• Future sales of shares by existing shareholders could cause the share price to decline.
• The company does not anticipate paying cash dividends in the foreseeable future.
• Executive officers, directors, and principal shareholders have the ability to control or significantly influence matters submitted to shareholders for approval.
• Lack of equity research analyst coverage or unfavorable reports could cause share price and trading volume to decline.
• Ability to use Net Operating Loss (NOL) carryforwards and other tax attributes may be limited due to ownership changes.
• Business could be adversely affected by macroeconomic conditions, including economic downturns, inflation, interest rate increases, natural disasters, public health crises, and geopolitical events.

Future Outlook

The company anticipates initiating multiple clinical trials in 2026, including monotherapy trials for CR-002 and CR-003, and the first CR-001 ADC combination trial. Proof-of-concept clinical data for CR-001 from the ASCEND trial and initial data for CR-003 from China are expected in the first quarter of 2027, with combination trial data by year-end 2027. The strategy involves expanding the product portfolio through internal development, the Paragon relationship, and external sources, with a vision to establish market leadership in oncology.

Management Comments

• We have a bold vision to build the next leading biotechnology oncology company.
• We believe the emerging data from the clinical development of ivonescimab supports the rationale for developing CR-001 in light of CR-001 and ivonescimab sharing the same mechanism of action.
• We believe that CR-001 has the potential to deliver improved clinical efficacy and safety over Keytruda, which is the best-selling drug in the world and is approved for the treatment of numerous cancers.
• We believe that CR-002 has the potential to have improved anti-tumor activity and tolerability compared to other PD-L1 directed ADCs.
• We believe that CR-003 has the potential to deliver potent antitumor activity based on its improved potency and half-life in preclinical models.
• We believe that the similarity between CR-001 and ivonescimab will enable it to apply insights from the clinical development of ivonescimab to that of CR-001, potentially accelerating timelines and reducing the number of patients in late-stage trials.
• We envision multiple opportunities to establish and maintain market leadership in oncology through careful selection of ADC products based on targets and payloads.

Industry Context

StockSavvy.ai notes that Crescent Biopharma is positioning itself in the highly competitive oncology market, specifically targeting immune checkpoint inhibitors and antibody-drug conjugates (ADCs). The company's lead candidate, CR-001, aims to compete with established blockbusters like Merck's Keytruda, leveraging a bispecific PD-1 x VEGF mechanism validated by ivonescimab (Akeso Biopharma/Summit Therapeutics). The ADC pipeline (CR-002, CR-003) is entering a rapidly growing market, with 2025 sales of nearly $13 billion and projected growth to over $41 billion by 2035. The strategy of combining CR-001 with ADCs aligns with emerging industry trends showing synergistic activity, as seen with Trodelvy (Gilead Sciences) and pembrolizumab combinations. The reliance on in-licensed intellectual property and third-party manufacturing is common for early-stage biotechs but also introduces significant operational and geopolitical risks, particularly with China-based partners like Kelun and WuXi Biologics, given recent U.S. legislative actions like the BIOSECURE Act.

Comparison to Industry Standards

• CR-001 is designed to incorporate the targeting, binding, cooperativity, and pharmacokinetics of ivonescimab, which demonstrated a statistically significant and clinically meaningful improvement in median Progression-Free Survival (PFS) of 11.1 months compared to 5.8 months for pembrolizumab (Keytruda) in the HARMONi-2 Phase 3 trial in NSCLC.
• CR-002 is differentiated from other PD-L1 directed ADCs (e.g., Pfizer's SGN-PDL1V, Henlius' HLX43) by its superior internalization, stable GGFG peptide linker, and topoisomerase inhibitor payload, which has shown higher antitumor activity and increased tolerability in other ADCs like Enhertu and Dato-DXd compared to microtubule inhibitors.
• CR-003 (SKB105) demonstrated superior cell internalization in low antigen density cancer cell lines and potent in vivo antitumor activity in NCIH358 NSCLC and CFPAC-1 pancreatic CDX tumor models, leading to tumor shrinkage, compared to SGN-B6A (Pfizer's sigvotatug vedotin) which at best delayed tumor growth.
• The combination of immune checkpoint inhibitors and ADCs with topoisomerase payloads is a growing area, with third-party results like Trodelvy plus pembrolizumab showing a median PFS of 11.2 months versus 7.8 months for chemotherapy plus pembrolizumab in TNBC, supporting Crescent's combination strategy.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings or claims are currently pending against the company as of December 31, 2025.

Related Party Transactions

• Fairmount Funds Management LLC (Fairmount) beneficially owns more than 5% of the company's voting securities, has two representatives on the Board (Peter Harwin and Jonathan Violin), and beneficially owns more than 5% of Paragon Therapeutics, Inc. (Paragon).
• In September 2024, Pre-Merger Crescent issued 20,000,000 shares of Series Seed Preferred Stock to Fairmount (through an affiliate fund) for $4.0 million.
• In October 2024, Pre-Merger Crescent issued $37.5 million in Convertible Notes, of which Fairmount (through an affiliate fund) held $15.0 million.
• Paragon Therapeutics, Inc. and Parascent Holding LLC (Parascent) were parties to the Antibody Paragon Option Agreement and ADC Paragon Option Agreement, under which the company licensed intellectual property for CR-001 and CR-002.
• The company paid Paragon $16.7 million for CR-001 development costs, $13.9 million for CR-002 development costs, and $2.2 million for Former CR-003 discovery efforts as of the filing date.
• Parascent was granted warrants to purchase 402,731 ordinary shares on December 31, 2025, and will be granted an additional 34,566 warrants on March 26, 2026, in connection with the termination of the ADC Paragon Option Agreement.
• Joshua Brumm, Jonathan McNeill, Ellie Im, Jan Pinkas, Richard Scalzo, Ryan Lynch, and Barbara Bispham are executive officers with employment offer letters and equity compensation.
• Peter Harwin and Jonathan Violin, as directors, have affiliations with Fairmount, which has significant influence over the company.

Stakeholder Impact

• **Shareholders**: Potential for dilution from future equity financings; significant influence of Series A Preferred Shareholders (Fairmount) on board decisions; share price volatility due to early-stage development and reliance on clinical trial outcomes; potential for capital appreciation if product candidates are successful.
• **Employees**: Dependent on key personnel, with plans for significant organizational growth; competitive compensation packages and benefits offered; subject to insider trading and clawback policies.
• **Customers (future)**: Aim to provide transformative therapies for cancer patients, addressing unmet medical needs; product efficacy, safety, convenience, and pricing will be key factors for market acceptance.
• **Suppliers/Contractors**: Continued reliance on third-party CROs and CMOs for research, development, and manufacturing, including those in China, which introduces supply chain and geopolitical risks.
• **Creditors**: Debt financing, if pursued, would create claims superior to shareholders; current convertible notes have been converted to equity, reducing debt burden.
• **Regulatory Authorities**: Subject to extensive and complex regulations (FDA, EMA, NMPA) for drug development, approval, manufacturing, and commercialization; compliance is critical and non-compliance could lead to significant penalties and delays.

Next Steps

• Initiate Phase 1/2 trial of CR-002 in the second half of 2026.
• Initiate Phase 1/2 trial of CR-003 (SKB105) in China in the first quarter of 2026.
• Initiate the first CR-001 ADC combination trial in the second half of 2026.
• Report proof-of-concept clinical data from the ASCEND trial for CR-001 in the first quarter of 2027.
• Receive initial data from Kelun's Phase 1/2 trial for SKB105 (CR-003) in China in the first quarter of 2027.
• Initiate a CR-001 and CR-003 combination trial in early 2027, with first data expected by year-end 2027.
• Continue to expand the product portfolio through internal development, the Paragon relationship, and external sources.
• Submit an Investigational New Drug (IND) application to the FDA for CR-002 in mid-2026.

Key Dates

Keywords

Biotechnology, Oncology, Cancer Therapy, Clinical Stage, CR-001, PD-1 x VEGF Bispecific Antibody, Antibody-Drug Conjugates (ADCs), CR-002, PD-L1 ADC, CR-003, ITGB6 ADC, Kelun Biopharma, Paragon Therapeutics, SEC Filing, 10-K, Clinical Trials, Drug Development, Immunotherapy, Solid Tumors, Nasdaq Capital Market, Biopharma Investment